NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/08/2026 10:03
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,097.75 mln
Float55.04 mln
Earnings Date07/31/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.39
Reliable
1-Year Forecast
118
Exceptional upside
Relative Strength
23
/ 100
Significantly lagging
Debt / Equity
0.05
Debt-free
ROE
-27.05
Deeply negative
Business Description
Kymera Therapeutics is a clinical-stage drug development company founded in 2015 and based in Watertown, Massachusetts. The company creates oral medicines that work by directing the body's own waste-disposal system to eliminate proteins that drive disease. Its pipeline targets conditions ranging from skin and lung diseases to autoimmune disorders and cancer, with several candidates already in human trials. Kymera also partners with Sanofi to advance one of its key programs in immunology and inflammation.
